With the introduction of the first recombinant protein therapeutic in 1982, the market for biologics started to grow at high rates, resulting in the demand for adequate production technologies. In 2005, the small start-up company Cellca GmbH was founded with the mission to fulfill the by then still unmet need for an efficient cell line development and bioprocessing platform, which is tailor-made for the requirements of the biopharmaceutical industry. This talk will tell the success story of Cellca and its cell line development technology from the beginnings over the acquisition by Sartorius in 2015 until today. It will show how the platform was and is continuously improved to solve challenges like the need to reduce time-to-market, development and manufacturing costs as well as the increasing molecule complexity and product quality demands.
- Our CHO CLD platform was continuously improved over many years resulting in one of the leading technologies on the market
- Also, today dedicated teams of experts are working non-stop to further optimize the technology
